Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
REPL 
Replimune Group Inc (REPL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/13/2025: REPL (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $4.86
1 Year Target Price $4.86
| 3 | Strong Buy |
| 5 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -69.96% | Avg. Invested days 42 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/13/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 409.79M USD | Price to earnings Ratio - | 1Y Target Price 4.86 |
Price to earnings Ratio - | 1Y Target Price 4.86 | ||
Volume (30-day avg) 8 | Beta 0.67 | 52 Weeks Range 2.68 - 17.00 | Updated Date 08/12/2025 |
52 Weeks Range 2.68 - 17.00 | Updated Date 08/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.24 |
Earnings Date
Report Date 2025-08-06 | When Before Market | Estimate -0.8429 | Actual -0.95 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -36.45% | Return on Equity (TTM) -73.44% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 82780191 | Price to Sales(TTM) - |
Enterprise Value 82780191 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.24 | Shares Outstanding 78055800 | Shares Floating 49644299 |
Shares Outstanding 78055800 | Shares Floating 49644299 | ||
Percent Insiders 2.01 | Percent Institutions 106.79 |
Upturn AI SWOT
Replimune Group Inc
Company Overview
History and Background
Replimune Group Inc. was founded in 2015. It is a biotechnology company focused on developing oncolytic immunotherapies to treat cancer. It went public in 2018. Replimune's approach involves using genetically modified viruses to selectively replicate within tumors, causing tumor cell death and stimulating an immune response against the cancer.
Core Business Areas
- Oncolytic Immunotherapy Development: Replimune's core business is the research and development of oncolytic immunotherapies, specifically engineered viruses that selectively infect and destroy cancer cells while stimulating an anti-tumor immune response.
Leadership and Structure
Philip Astrow is the Chief Executive Officer. The company has a typical organizational structure for a biotechnology firm, with departments focused on research, clinical development, manufacturing, and commercial operations.
Top Products and Market Share
Key Offerings
- RP1 (vusolimogene oderparepvec): RP1 is Replimune's lead product candidate, an oncolytic virus being developed for various solid tumors, including cutaneous squamous cell carcinoma (CSCC), melanoma, and non-melanoma skin cancers. Market share data is not yet applicable as it is still in clinical development. Key competitors are companies developing similar oncolytic viruses or other immunotherapies, such as Amgen (T-VEC) and other companies with checkpoint inhibitors like Merck (Keytruda).
Market Dynamics
Industry Overview
The oncolytic virus therapy market is a growing segment of the broader immuno-oncology market. It is driven by the need for more effective and targeted cancer treatments with fewer side effects. The industry is characterized by innovation and increasing investment in research and development.
Positioning
Replimune is positioned as a leader in the oncolytic virus therapy space, with a focus on developing potent and immunogenic oncolytic viruses. Its competitive advantages include its proprietary Immulytic platform and its focus on combination therapies.
Total Addressable Market (TAM)
The overall immuno-oncology market is projected to reach hundreds of billions of dollars. Replimune is positioned to capture a portion of this TAM through its oncolytic virus therapies, focusing initially on specific tumor types with high unmet needs. The specific TAM for RP1 and other pipeline products depends on regulatory approvals and market penetration.
Upturn SWOT Analysis
Strengths
- Proprietary Immulytic platform
- Strong preclinical and clinical data for RP1
- Experienced management team
- Focus on combination therapies
Weaknesses
- Reliance on a single lead product candidate (RP1)
- High cash burn rate
- Dependence on clinical trial success
- Manufacturing complexity
Opportunities
- Potential for RP1 to become a blockbuster drug
- Expansion of pipeline with new oncolytic virus candidates
- Partnerships with pharmaceutical companies
- Expansion into new cancer indications
Threats
- Clinical trial failures
- Competition from other oncolytic viruses and immunotherapies
- Regulatory hurdles
- Manufacturing challenges
- Adverse events related to the treatment
Competitors and Market Share
Key Competitors
- AMGN
- MRK
- BMY
Competitive Landscape
Replimune competes with other companies developing oncolytic viruses and immunotherapies. Its advantages include its proprietary Immulytic platform and focus on combination therapies. Disadvantages include its reliance on a single lead product candidate and high cash burn rate. Amgen's T-VEC is an approved oncolytic virus therapy for melanoma, and companies like Merck and Bristol Myers Squibb have established checkpoint inhibitors.
Growth Trajectory and Initiatives
Historical Growth: Growth has been primarily in terms of clinical development and pipeline expansion, rather than revenue. The company has progressed RP1 through multiple clinical trials.
Future Projections: Future growth depends on the successful development and commercialization of RP1 and other pipeline candidates. Analyst estimates vary widely depending on the perceived probability of success.
Recent Initiatives: Recent initiatives include advancing RP1 in multiple clinical trials, expanding the pipeline with new oncolytic virus candidates, and pursuing partnerships with pharmaceutical companies.
Summary
Replimune is a clinical-stage biotech company with a promising oncolytic virus platform. Their lead product, RP1, shows potential, but the company faces risks common to drug development, including clinical trial success and regulatory approval. The company's high cash burn rate needs to be managed carefully, and success hinges on data. Overall, Replimune has potential but has a long way to go.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Replimune Group Inc. SEC filings
- Analyst reports
- Company website
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on publicly available data and may not be entirely accurate or complete. Investment decisions should be made based on individual due diligence and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Replimune Group Inc
Exchange NASDAQ | Headquaters Woburn, MA, United States | ||
IPO Launch date 2018-07-20 | CEO & Director Dr. Sushil Patel Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 479 | Website https://www.replimune.com |
Full time employees 479 | Website https://www.replimune.com | ||
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3, which express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.